Mainstreaming Addiction Treatment Act of 2021
A BILL
To amend section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to eliminate the separate registration requirement for dispensing narcotic drugs in schedule III, IV, or V (such as buprenorphine) for maintenance or detoxification treatment, and for other purposes.
Sec. 2 Eliminating separate registration requirement for dispensing narcotic drugs in schedule III, IV, and V for maintenance or detoxification treatment
Sec. 3 National education campaign
Sec. 4 Community health aides and community health practitioners
“(i) while the patient is—
“(I) being treated by, and physically located in, a hospital or clinic registered under section 303(f); or
“(II) for purposes of section 302(h), being treated by a community health aide or community health practitioner; and”
“(60) The terms community health aide and community health practitioner have the meanings given to such terms for purposes of section 119 of the Indian Health Care Improvement Act (25 U.S.C. 1616l).”
“(h) Dispensation of narcotic drugs in schedule III, IV, or V by certain practitioners
“(1) In general—Notwithstanding subsection (a)(2), a community health aide or community health practitioner may dispense a narcotic drug in schedule III, IV, or V, such as buprenorphine, or a combination of such drugs, to an individual for maintenance treatment or detoxification treatment (or both) without being registered under this title if the drug is prescribed by a practitioner through the practice of telemedicine.
“(2) Preemption—Notwithstanding section 708, a State may not require a community health aide or community health practitioner to be licensed by the State in order to dispense narcotic drugs in accordance with paragraph (1) of this subsection.”